Bioxcel, Llc

Bioxcel, Llc company information, Employees & Contact Information

Explore related pages

Related company profiles:

BioXcel LLC utilizes advanced technologies such as AI (Artificial Intelligence) to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel is optimizing research and development for productivity and creating novel and transformative medicines (or drugs). BioXcel's AI-enabled platform, EvolverAI helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process.

Company Details

Employees
48
Founded
-
Address
555 Long Wharf Drive,
Phone
203 957 2487
Email
in****@****cel.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New Haven, Connecticut
Looking for a particular Bioxcel, Llc employee's phone or email?

Bioxcel, Llc Questions

News

BioXcel Therapeutics Rings the Closing Bell - Nasdaq

BioXcel Therapeutics Rings the Closing Bell Nasdaq

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October - GlobeNewswire

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October GlobeNewswire

BioXcel to seek at-home approval for agitation drug after upbeat study - PharmaLive

BioXcel to seek at-home approval for agitation drug after upbeat study PharmaLive

BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On? - Benzinga

BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On? Benzinga

UNC School of Medicine, BioXcel Therapeutics Team Up to Tackle Acute Stress Disorder - UNC Health

UNC School of Medicine, BioXcel Therapeutics Team Up to Tackle Acute Stress Disorder UNC Health

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® - Yahoo Finance

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI® Yahoo Finance

BioXcel Therapeutics Submits Pre-Supplemental New Drug - GlobeNewswire

BioXcel Therapeutics Submits Pre-Supplemental New Drug GlobeNewswire

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - GlobeNewswire

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering - GlobeNewswire

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering GlobeNewswire

BioXcel Therapeutics Announces Reverse Stock Split - GlobeNewswire

BioXcel Therapeutics Announces Reverse Stock Split GlobeNewswire

BioXcel Therapeutics Provides Clinical and Business Update - GlobeNewswire

BioXcel Therapeutics Provides Clinical and Business Update GlobeNewswire

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia GlobeNewswire

BioXcel Therapeutics Announces Positive FDA Pre-sNDA - GlobeNewswire

BioXcel Therapeutics Announces Positive FDA Pre-sNDA GlobeNewswire

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Yahoo Finance

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Yahoo Finance

BioXcel's Breakthrough Agitation Drug Targets 23M Episodes Annually: Phase 3 Data Due This Month - Stock Titan

BioXcel's Breakthrough Agitation Drug Targets 23M Episodes Annually: Phase 3 Data Due This Month Stock Titan

Biotech Firm BioXcel Therapeutics Secures Future on Nasdaq After Meeting $35M Market Value Threshold - Stock Titan

Biotech Firm BioXcel Therapeutics Secures Future on Nasdaq After Meeting $35M Market Value Threshold Stock Titan

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 GlobeNewswire

BioXcel Therapeutics announces $7M public offering - Hartford Business Journal

BioXcel Therapeutics announces $7M public offering Hartford Business Journal

BioXcel stock down despite late-stage trial win (BTAI:NASDAQ) - Seeking Alpha

BioXcel stock down despite late-stage trial win (BTAI:NASDAQ) Seeking Alpha

2,600+ Patient Episodes: BioXcel's Groundbreaking Phase 3 Trial for First At-Home Agitation Treatment - Stock Titan

2,600+ Patient Episodes: BioXcel's Groundbreaking Phase 3 Trial for First At-Home Agitation Treatment Stock Titan

BioXcel Therapeutics raises $14M in direct offering - Hartford Business Journal

BioXcel Therapeutics raises $14M in direct offering Hartford Business Journal

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of GlobeNewswire

BioXcel to seek label update for psych drug after Phase 3 success - Endpoints News

BioXcel to seek label update for psych drug after Phase 3 success Endpoints News

BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label - Stocktwits

BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label Stocktwits

BioXcel Therapeutics announces $60M proposed public offering - Hartford Business Journal

BioXcel Therapeutics announces $60M proposed public offering Hartford Business Journal

New Haven-based BioXcel faces delisting from Nasdaq stock exchange - Hartford Business Journal

New Haven-based BioXcel faces delisting from Nasdaq stock exchange Hartford Business Journal

BioXcel's AI platform repurposes neuropsychiatric drugs - drugdiscoverytrends.com

BioXcel's AI platform repurposes neuropsychiatric drugs drugdiscoverytrends.com

Is BioXcel Stock Ready to Boom? - timothysykes.com

Is BioXcel Stock Ready to Boom? timothysykes.com

Missed trial protocols, fabricated emails and failed endpoint mar BioXcel's Alzheimer's agitation readout - Fierce Pharma

Missed trial protocols, fabricated emails and failed endpoint mar BioXcel's Alzheimer's agitation readout Fierce Pharma

After FDA found misconduct at trial site, BioXcel touts result from 3rd-party audit and eyes filing - Fierce Pharma

After FDA found misconduct at trial site, BioXcel touts result from 3rd-party audit and eyes filing Fierce Pharma

The Next Evolution In Drugs? AI, According To One CEO - Investor's Business Daily

The Next Evolution In Drugs? AI, According To One CEO Investor's Business Daily

BioXcel's Struggles: From FDA Issues To Financial Instability (NASDAQ:BTAI) - Seeking Alpha

BioXcel's Struggles: From FDA Issues To Financial Instability (NASDAQ:BTAI) Seeking Alpha

BioXcel Securities Class Action Dismissed - Law.com

BioXcel Securities Class Action Dismissed Law.com

BioXcel will use $260M finance deal to expand indications for schizophrenia drug - Fierce Biotech

BioXcel will use $260M finance deal to expand indications for schizophrenia drug Fierce Biotech

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority - GlobeNewswire

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority GlobeNewswire

Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer - Fierce Biotech

Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer Fierce Biotech

Top Bioxcel, Llc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant